This article covers multiple oral and poster presentations dedicated to gene therapy as a treatment for haemophilia A and B, which took place at the International Society on Thrombosis and Haemostasis (ISTH) Congress, 9th–13th July 2022. The article highlights updates from clinical trials of adeno-associated virus-based gene therapy products, guidance on the real-world monitoring of patients with haemophilia who have received gene therapy, and accentuates the unmet needs and challenges associated with gene therapy.
EMJ Hematology 10 [Supplement 5] . 2022
September 2022
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/07/Filgrastim-Prophylaxis-for-Neutropenia-in-Myelodysplasia-Pre-Surgery-Case-Report-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Diffuse-Large-B-Cell-Lymphoma-of-Spleen-A-Key-Differential-of-Nodular-Splenomegaly-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/The-Impact-of-‘Pre-conception-on-Conception-An-Inadvertent-Form-of-Infertility-Web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/07/Hema_Article_Waheed-940x564.jpg)